Title: Johnson & Johnson (NYSE:JNJ) Shares React as FDA Grants Multiple Designations to Nipocalimab
Date: 2025-04-09 18:09
URL: https://finance.yahoo.com/news/johnson-johnson-nyse-jnj-shares-180948855.html?.tsrc=rss

Oops, something went wrong Tip: Try a valid symbol or a specific company name for relevant results Oops, something went wrong March's report could be last time investors see inflation easing. Here's what to expect. Stocks wanted one thing from Trump after his shocking tariff announcement last week. They finally got it today. Stocks staged a wild rally after Trump's tariff reversal. The Dow gained near 3,000 points and the S&P 500 had its best day since 2008. Trump nodded to market turbulence as a factor in his 'reciprocal' tariff pause, saying investors were 'yippy' and 'afraid' The Nasdaq was up 10%, aiming for its biggest gain since 2008, after Trump paused some tariffs. The Dow soared 2,500 points. Trump unilaterally raises tariff rate on China to 125%, pauses 'reciprocal' tariffs on other countries The major indexes rocketed higher after Trump announced a '90-day pause on tariffs for most countries. Investors grapple with bond chaos as long-term yields soar following Trump's sweeping tariffs Trump tries to reassure Americans as markets reel from tariff shocks JPMorgan's Dimon: US recession now a 'likely outcome' Dow slides, Nasdaq rises after China strikes back against Trump's tariffs China strikes back by raising tariff on US goods to 84% after Trump's massive duties take effect What rankles Elon Musk the most — and what he actually likes — about Trump's trade approach A diminished ‘Magnificent 7’ tests Big Tech’s role in the market Trump tariffs live updates: US moves forward with 104% China tariffs, other 'reciprocal' duties go into effect Low mortgage rates from tariff pain? Don't count on it. Bill Ackman is waging a public campaign to sway Trump's tariffs. Here's what the billionaire says should happen next. Tariff-fueled losses for the megacaps have topped $2 trillion, as Tesla and Apple led Tuesday's sell-off Stocks completed a remarkable U-turn, with the Dow ending 300 points lower as Trump's tariffs sparked more volatility The S&P 500 and Nasdaq turned red after an early rally, as the White House said Trump would move forward with 104% China tariffs. Markets are wrestling with a mystery: What exactly does Trump want from tariff talks? Dow, S&P 500, Nasdaq surge in Wall Street rebound as hopes for Trump tariff deals get a boost Wall Street got a preview of what could stop the tariff turmoil 'No signal, lots of noise': Sell-off cools down as Trump's tariffs drive wild swings in stock market Some of Trump's closest allies, including Elon Musk and Bill Ackman, are starting to raise questions about his tariff team The Trump stock market crash will hurt Main Street more than Wall Street Dow sinks 350 points, S&P 500 falls for third straight day as tariffs send stocks on roller-coaster ride BlackRock's Fink says most CEOs tell him 'we are probably in a recession right now' Wall Street bulls are ripping up their forecasts as the market's tariff-fueled meltdown 'projects negative outcomes to infinity' Trump threatens additional tariffs on China if it doesn't scrap its plans for retaliation Stocks whipsawed in volatile trading as investors sought clarity on tariff developments. See the latest updates. Dow, S&P 500, Nasdaq plummet as Trump tariff rout set to continue Jamie Dimon warns of slower growth, higher inflation as tariffs add 'one large additional straw on the camel’s back' Dow, S&P 500, Nasdaq futures plunge as Trump tariff rout gets set to escalate Trump says markets may have to 'take medicine' as stock futures plummet Analysts say stocks have 'ample space' to keep selling off as Trump and top advisers dig in on tariffs Stock futures plunge as Trump tariff rout looks set to intensify Homebuyers waiting for lower mortgage rates may wonder if rates will ever get to 3% again. Here's what to know. Opinion: There are too many unknowns to be able to model a clean market forecast right now. Builders sitting on a pile of unsold homes are slashing prices and offering mortgage rate deals Trump administration officials appeared on Sunday shows as markets brace for more turmoil 'Too late to panic': Wall Street strategists warn messy tariff fallout won't go away anytime soon Tariff fallout in focus after stocks' worst week since 2020: What to know this week How to protect your money during economic turmoil, stock market volatility Tax day 2025 is coming up. Here’s what to know to file by the deadline. Elon Musk says Europe and the US should move to a "zero-tariff situation." The EU is currently set to face a 20% US tariff. Trump's tariffs stoke concerns that 'Republicans can kiss goodbye to their majority' in 2026 So, what happens during stagflation? And how does it impact your wallet? US customs began collecting the new 10% tariff on imports early on Saturday morning. Follow our liveblog for updates. A dealmaking freeze and the biggest stocks rout since 2023 are raising the stakes for Wall Street’s earnings season Johnson & Johnson announced compelling results from its Phase 3 Vivacity-MG3 study on nipocalimab, showing promising efficacy and safety in treating generalized myasthenia gravis, which were significant events during the quarter. Additionally, the company's ongoing regulatory strides, including new designations for nipocalimab, offered a robust pipeline outlook. However, despite a 5% stock increase in the last quarter, JNJ's performance remained largely aligned with market movements, which experienced a volatile phase due to broad economic uncertainties and tariff concerns. These developments provided some support against a backdrop of overall market downturns. We've spotted 1 possible red flag for Johnson & Johnson you should be aware of. AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. The compelling results from Johnson & Johnson's Phase 3 study on nipocalimab could significantly bolster its portfolio in treating generalized myasthenia gravis, potentially leading to increased market confidence and improved revenue streams. This progress aligns with their strategic focus on expanding treatment options, which may positively influence revenue and earnings forecasts. Over the past five years, JNJ's total return, including dividends, was 18.19%, indicating solid long-term growth. In the last year, JNJ surpassed the US Pharmaceuticals industry, which saw an 11.5% decline, demonstrating resilience against broader industry challenges. Despite the promising data and a subsequent 5% stock increase last quarter, the stock remains priced below the consensus price target of $171.11, reflecting a 9.4% potential upside from its current US$153.25 level. These share price dynamics suggest investor caution amid macroeconomic pressures. As analysts project revenue to grow 2.9% annually with improved profit margins, any positive regulatory developments related to nipocalimab could further justify the stock moving towards its price target, potentially enhancing the company's market position and shareholder value. Explore historical data to track Johnson & Johnson's performance over time in our past results report.  This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:JNJ. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com Single-use plastic packaging continues to drive fossil fuel extraction, despite brands’ promises to cut back, according to climate group Stand.earth. Trump's tariffs may not hit US real estate investment trusts (REIT) head on, but according to a new note from Bloomberg Intelligence, if the economy cools and rates drop, rates could feel the ripple effect. Bloomberg Intelligence Jeffrey Langbaum has more on the story. The authorisation was based on data from the multicentre Phase III SELECT-GCA trial. Coming into Tuesday trading, the shares had lost 17.5% over the past three trading sessions, which followed President Donald Trump’s “Liberation Day.” I have $120,000 in after-tax contributions in my traditional 401(k) at work. Can I roll over just the after-tax money into my Roth IRA? I would like to avoid creating a taxable event. – Daniel Daniel, this is a great question. Your ability to roll over these after-tax 401(k) contributions to your Roth IRA may […] The post Ask an Advisor: Can I Roll Over $120k in After-Tax 401(k) Contributions to a Roth IRA Without Paying Taxes? appeared first on SmartReads by SmartAsset. Wondering how long to keep tax documents? Here’s what to know about federal and state guidelines and how to properly dispose of tax documents when you’re ready. Is it wise to start converting my 401(k) into an IRA (and then Roth) by 10% per year in order to avoid having to claim too much income each year when converting and also avoid RMDs as much as I can? -Cathy It's definitely smart to be thinking about this, Cathy. Systematic Roth conversions like […] The post Ask an Advisor: Is it Wise to Convert 10% of My 401(k) into a Roth IRA Each Year to Avoid Taxes and RMDs? appeared first on SmartReads by SmartAsset. These are the largest publicly traded companies and members of the trillion-dollar club. Your mid-fifties is a good time to do a retirement check. To be clear, you should always have at least one eye on retirement. This isn't something to ever forget entirely. But most of the time, that means nothing more than making sure your annual contributions go through in-full, on-time and to the right places, […] The post What’s a Realistic Retirement Budget? I’m 55 With $490k Saved, Making $80,000 Annually. appeared first on SmartReads by SmartAsset. Credit utilization is a big part of your credit score, and you should take steps to manage it well. Tip: Try a valid symbol or a specific company name for relevant results Sign in to access your portfolio 


Try again.
